Form 4: Anixa Biosciences CEO Exercises Stock Options

Anixa Biosciences CEO Amit Kumar exercised 200,000 stock options, acquiring shares and having a portion withheld for taxes and exercise costs.

Summary

• Anixa Biosciences Inc. CEO, Amit Kumar, executed a transaction on October 30, 2025, involving the exercise of employee stock options.
• Kumar acquired 200,000 shares of Common Stock through the exercise of options at a price of $2.92 per share.
• Concurrently, 169,439 shares of Common Stock were disposed of at a price of $4.06 per share to cover the exercise price of the options and satisfy tax withholding obligations.
• Following these transactions, Kumar's direct beneficial ownership of Common Stock stands at 610,486 shares.
• The stock options were exercised due to their upcoming expiration on February 18, 2026.
• The original stock option grant date was February 18, 2016, with vesting occurring in 36 consecutive monthly installments beginning March 31, 2016.

Sentiment

Score: 5

Explanation: The filing reports a mandatory insider transaction (exercise of expiring options) with no discretionary sale of shares by the CEO, making it a neutral event in terms of sentiment.

Positives

• CEO Amit Kumar did not sell any shares beyond what was necessary to cover the exercise price and tax withholding obligations, indicating a continued holding of equity in Anixa Biosciences Inc.

Future Outlook

This filing, a Form 4, reports an insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The reporting person exercised the stock options at this time due to their upcoming expiration on February 18, 2026.
• Dr. Kumar did not sell any shares in connection with the exercise of the options beyond those withheld by Anixa Biosciences, Inc. to cover the exercise price and satisfy tax withholding obligations.

Industry Context

This Form 4 filing details a routine insider transaction, specifically the exercise of expiring stock options by a company executive. Such transactions are common and typically do not reflect broader industry trends or competitive dynamics, but rather individual compensation and equity management strategies.

Stakeholder Impact

• Shareholders: The transaction results in a slight increase in the number of outstanding shares due to option exercise, but the CEO's continued equity holding (after mandatory withholding) may be viewed positively as it aligns his interests with shareholders.

Key Dates

Keywords

Anixa Biosciences, ANIX, Amit Kumar, CEO, Stock Options, Insider Transaction, Form 4, Equity